GLP-1s are still prescription medicines. But the way patients find, choose, access and stay on them is starting to look a lot like consumer health.
GLP-1s are driving business model innovation in pharma, making parts of the traditional Rx model look increasingly like consumer health. At the same time, consumer health companies see an opening to position their products as companions to GLP-1 treatment, supporting patients on their weight loss journeys.
In this Scrip and HBW Insight webinar, senior voices from pharma, consumer health and strategy consulting explore what each side can teach the other. You will leave with a clearer view of how the patient journey is being redrawn, where the strongest partnership opportunities sit, and what it takes to win and keep GLP-1 patients.
Melanie Raouzeos-Haid
CVP Medical and Marketing, Region Emerging Markets
View profile

CVP Medical and Marketing, Region Emerging Markets
Novo Nordisk
Andy Roberts
SVP New Growth Platforms
View profile

SVP New Growth Platforms
Bayer Consumer Health
Christian Ring Danelund
Senior Director
View profile

Senior Director
Simon-Kucher & Partners
Aakash Babu
Managing Editor
View profile

Managing Editor
Pink Sheet, Scrip
Aakash Babu has covered the pharmaceutical sector since 2018, starting his career at Reuters, where he specialised in tackling company news. Just before joining the Citeline team, he worked as a healthcare analyst at the Economist Group, focusing on disease trends, drug development, regulatory changes and pharmaceutical pricing. He has a master’s in economics and a post-graduate specialisation in business journalism from Asian College of Journalism-Bloomberg. He was a key member of the team that covered the initial breakthroughs in COVID-19 vaccine research during his time at Reuters. He also has experience in forecasting regulatory trends, drug approvals and pharmaceutical sales. Outside of work he enjoys traveling, writing and watching football.
Tom Gallen
Managing Editor
View profile

Managing Editor
HBW Insight
Tom reports and edits European consumer health care industry news and analysis. Leading HBW Insight’s health and wellness coverage in Europe, he has been writing about the sector since 2013. Tom’s main focus is analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios. He also reports on regulatory topics such as novel foods and prescription-to-OTC switches.
GLP-1s remain prescription medicines, but patients now research, compare and buy treatment in ways that resemble consumer health. That creates openings for both sides: pharma can borrow consumer health’s strengths in brand building and omnichannel activation, while consumer health can reach a defined, health-engaged patient population.
Can’t make the live date? Register anyway and you’ll receive the recording once the event has taken place.
Choose a time to talk
専門家との相談日時を選択
Calendar requires cookies. Enable cookies
カレンダーの表示にはCookieの有効化が必要です Cookieを有効にする
Or send us a message and we'll be in touch
面談の有無がお決まりでない場合は、お問い合わせ内容をお送りください。担当者よりご連絡いたします。